Model for the role of bortezomib in SRSF2-mutated MDS. (A) In SRSF2-mutant (mt) MDS, IFN only suppresses WT cells with SRSF2-mt cells being spared as they have lower levels of STAT1. (B) Bortezomib upregulates STAT1 in SRSF2-mt cells rendering them sensitive to IFN, allowing a relative expansion of WT cells, which are not affected by bortezomib. Normal WT hematopoietic cells are depicted in blue and SRSF2-mt cells in burgundy. Professional illustration by Somersault18:24.